Argenx SE
ARGX
Clasificación en acciones
#448
argenx SE, a biotechnology company established in Amsterdam, the Netherlands,... argenx SE, a biotechnology company established in Amsterdam, the Netherlands, in 2008, is dedicated to developing innovative therapies primarily for autoimmune diseases. The company's operations span across key global markets, including the United States, Japan, Europe, the Middle East, Africa, and China. Its leading investigational therapy is efgartigimod, which is being developed to address a broad range of conditions. These include generalized myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary Sjögren's syndrome, post-COVID postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, ANCA-associated vasculitis, and antibody-mediated rejection. Also noted in connection with its lead product efforts is ENHANZE SC. The company's extensive development pipeline features several other promising candidates. Empasiprubart is in development for multifocal motor neuropathy, delayed graft function, and dermatomyositis. ARGX-119 is being investigated for congenital myasthenic syndrome and amyotrophic lateral sclerosis. Further pipeline assets include ARGX-213, which targets FcRn; ARGX-121 and ARGX-220, both designed to modulate the immune system; ARGX-109, which targets IL-6; and ARGX-118, developed for inflammatory indications. argenx is also advancing cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. The company’s portfolio encompasses several proprietary products and brands, such as VYVGART, VYVGART HYTRULO, VYVDURA, ARGENX, ABDEG, NHANCE, SIMPLE ANTIBODY, and ARGENXMEDHUB. Strategic collaborations are integral to argenx's business model. It maintains partnerships with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S, alongside numerous collaboration and license agreements with entities including Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. A specific collaboration with Genmab A/S focuses on the discovery, development, and commercialization of novel therapeutic antibodies for immunology and oncology applications. Additionally, argenx has a strategic collaboration with IQVIA Holdings Inc. for the provision of safety systems and related services.
Precio por acción
$875.26
Capitalización bursátil
$54.72B
Cambio (1 día)
6.01%
Cambio (1 año)
3.04%
País
NL
Comercio Argenx SE (ARGX)
Categoría
Healthcare
Ratio P/E de Argenx SE (ARGX)
Ratio P/E al October 2026 TTM: 30.33
Según los últimos informes financieros y el precio de las acciones de Argenx SE, el P/E actual (TTM) de la empresa es 30.33. Al final de 2023, la empresa tenía un P/E de -73.46.
Historial del ratio P/E de Argenx SE desde 2010 hasta 2026
Relación P/E al final de cada año
| Año | Ratio P/E | Cambiar |
|---|---|---|
| 2026 (TTM) | 30.33 | -39.77% |
| 2024 | 50.36 | -168.56% |
| 2023 | -73.46 | 157.20% |
| 2022 | -28.56 | -38.42% |
| 2021 | -46.38 | 156.77% |
| 2020 | -18.06 | -40.99% |
| 2019 | -30.60 | -23.89% |
| 2018 | -40.21 | 1.91% |
| 2017 | -39.45 | 195.63% |
| 2016 | -13.35 | 28.85% |
| 2015 | -10.36 | 8.55% |
| 2014 | -9.54 | -34.89% |
| 2013 | -14.65 | 51.49% |
| 2012 | -9.67 | -64.98% |
| 2011 | -27.63 | 0.00% |
| 2010 | 0.00 | 0.00% |
Relación P/E para empresas similares o competidores
| Empresa | P/E Ratio | Diferencia del P/E Ratio | País |
|---|---|---|---|
| 28.78 | -5.10% |
US
|
|
| -28.36 | -193.50% |
US
|
|
| -24.57 | -181.00% |
AU
|
|
| - | - |
CH
|
|
| 17.49 | -42.34% |
BE
|
¿Cómo leer un P/E ratio?
El ratio Precio/Beneficio (P/E Ratio) mide la relación entre el precio de las acciones de una empresa y sus beneficios por acción.
Un P/E bajo pero positivo indica una empresa con altos beneficios en relación a su valoración actual y que podría estar infravalorada. Una empresa con un P/E negativo alto (cerca de 0) indica fuertes pérdidas en comparación con su valoración.
Las empresas con un P/E superior a 30 o negativo suelen considerarse "acciones de crecimiento", lo que significa que los inversores esperan que crezca o se vuelva rentable en el futuro.
Las empresas con un P/E positivo inferior a 10 suelen considerarse "acciones de valor", lo que significa que ya son muy rentables y no se espera un fuerte crecimiento.